Beam Token
BEAM#156Beam Token (BEAM) News
The latest Beam Token (BEAM) news in one feed: protocol upgrades, partnership announcements, regulatory updates and price analysis, curated by BTI.
FDA Draft Could Reduce Repeated Work for Personalized Gene Edits
The FDA proposed one-license treatment for related individualized gene-editing variants. The framework could help modular platforms such as Prime Medicine's, but it remains nonbinding and does not relax core clinical evidence requirements.
Beam's First BEAM-301 Data Show Longer Fasting, With Important Safety and Scale Limits
Two of three patients at the 40 mg dose completed 15-hour controlled fasts and stopped daily starch supplements after BEAM-301. The result is promising, but it comes from six patients in an open-label early-stage trial.
ARKG Adds Four Biotech Positions While Trimming 10x Genomics
ARK Invest added Ionis, Veracyte, Beam and Scribe to its genomics ETF while trimming 10x Genomics. These transactions expose the fund to distinct drug-development and diagnostics catalysts, not a uniform biotech theme.